INDUSTRY MEMBER: Sermonix Pharmaceuticals

Sermonix Pharmaceuticals Inc is a privately held, Ohio-based biopharmaceutical company with a precision medicine focus for bringing targeted oncology products through development, approval, and commercialization. Sermonix’s lead candidate is oral lasofoxifene. Lasofoxifene is an investigational novel endocrine therapy in clinical development which has demonstrated robust target engagement as an antagonist at the breast particularly in the presence of ESR1 mutations. Lasofoxifene has unique tissue selectivity distinguishing it from other current and investigational endocrine therapies with beneficial effects seen on vagina and bone in previous clinical studies. Sermonix is currently focused on the study of lasofoxifene for advanced breast cancer treatment, particularly in patients with locally advanced or metastatic hormone receptor-positive (ER+)/human epidermal growth factor 2-negative (HER2-) breast cancer who have developed an ESR1 mutation.

Sermonix Pharmaceuticals PROGRAMS & RESOURCES

Clinical Trials

The ELAINE Study

The ELAINE studies are investigating oral drug, lasofoxifene, a novel targeted endocrine agent, in women and men with locally advanced or metastatic estrogen receptor-positive/human epidermal growth factor 2-negative (ER+/HER2-) breast cancer expressing an ESR1 mutation.

Link to program